Skip to content

Non-PI HAART a risk factor for glucose intolerance, finds study in HIV-positive US women

European warning about tenofovir/ddI, and BMS strengthens caution about use of efavirenz during pregnancy

HIV infection damages mitochondria in the absence of antiretroviral therapy

Fatty liver present in 40% of HIV/HCV coinfected patients: drug choice and weight may contribute

Mild neuropsychiatric disorders can persist for two years after starting efavirenz

Genetic differences predict triglyceride increase on ritonavir-boosted PI

HIV causes metabolic disturbances in the absence of antiretroviral therapy

Starting HAART with a CD4 cell count below 100 cells/mm3 a risk factor for IRIS, study finds

Treatment for bone mineral loss: alendronate safe and effective in HIV